Overview

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

Status:
Completed
Trial end date:
2019-11-27
Target enrollment:
Participant gender:
Summary
This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Vanda Pharmaceuticals
Treatments:
Iloperidone